1
|
Santurette CC, Charron M, Bouyer S, Houzé P, Binninger S, Lavergne A, Mercier M, Giraud C. Study of a new device for washing and concentrating cryopreserved hematopoietic stem cells and mononuclear cells: a single center experience. Cytotherapy 2021; 24:86-92. [PMID: 34690062 DOI: 10.1016/j.jcyt.2021.07.008] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/18/2021] [Revised: 07/16/2021] [Accepted: 07/16/2021] [Indexed: 11/29/2022]
Abstract
BACKGROUND AIMS Cryopreserved cellular products, as parts of hematopoietic progenitor cell (HPC) transplants, mononuclear cell reinjections for donor lymphocyte infusion or extracorporeal photopheresis, can be washed before being reinjected into the patient or infused directly, depending on local practices. The aim of washing is to reduce the incidence and severity of adverse reactions (ARs) due to the dimethyl sulfoxide (DMSO) used as a cryoprotective agent and other factors, such as dead cell debris. At the authors' cell therapy laboratory (CTL) in Poitiers, France, as in 76% of Etablissement Français du Sang (EFS) CTLs, all cryopreserved products undergo thawing in a water bath followed by washing with the COBE 2991. As this device will soon cease to be available, an alternative process needs to be assessed. METHODS The authors compared two closed systems: the authors' semi-automatic system using the traditional centrifugation method (COBE 2991) and an automated device using spinning membrane filtration (Lovo). A total of 72 HPC bags available for research were used. The authors first performed a paired comparison, processing one or two HPC bags washed by each device. A second study was carried out to compare two different washing solutions generally used by EFS CTLs along with variable storage conditions. Finally, the authors studied the efficiency of the Lovo with three or four thawed bags. The main parameters studied were viable CD34+ cell recovery and viability, CD3+ cell recovery, stability up to 6 h after washing, DMSO elimination and center feasibility. RESULTS The Lovo device showed better CD34+ cell recovery compared with the COBE 2991 while maintaining CD34+ viability and stability over 6 h. Moreover, Lovo efficiency seemed to be independent of the number of thawed bags processed and washing solution used in the authors' study. CD3+ cell recovery met the authors' internal specifications (cell recovery >50%), with similar results seen when processing with either the COBE 2991 or Lovo. Additionally, on average, 97% of DMSO was removed after washing with Lovo, minimizing the risk of ARs. The storage conditions post-processing indicated preferred storage conditions of 7 ± 3°C. Finally, if processing time seemed shorter using COBE 2991 for one bag washed, the Lovo device required only one staff member regardless of the number of HPC bags processed. CONCLUSIONS The Lovo device seems to provide an opportunity to standardize HPC processing, ensuring patient safety, with, on average, 97% of DMSO removed, while improving recovery of cells of interest and maintaining viability over time in case of delayed transplant. The Lovo device consequently seems to be a serious alternative to the COBE 2991.
Collapse
Affiliation(s)
- Catherine Chesnel Santurette
- Service Oncologie Hématologique et Thérapie Cellulaire, Centre Hospitalier Universitaire, Poitiers, France; Laboratoire d'Ingénierie Cellulaire, Etablissement Français du Sang, Poitiers, France.
| | - Mickaël Charron
- Laboratoire d'Ingénierie Cellulaire, Etablissement Français du Sang, Poitiers, France
| | - Sabrina Bouyer
- Laboratoire d'Hématologie Cellulaire, Centre Hospitalier Universitaire, Poitiers, France
| | - Pascal Houzé
- Laboratoire de Biochimie, Hôpital Universitaire Necker-Enfants Malades, Assistance Publique Hôpitaux de Paris, Paris, France
| | | | | | | | - Christine Giraud
- Service Oncologie Hématologique et Thérapie Cellulaire, Centre Hospitalier Universitaire, Poitiers, France; Laboratoire d'Ingénierie Cellulaire, Etablissement Français du Sang, Poitiers, France
| |
Collapse
|
2
|
Yafour N, Bekadja MA, Chevallier P, Cabrera Q, Coman T, Elkababri M, Hamzy F, Quessar A, Laamiri A, Pochon C, Yakoub-Agha I, Harif M. [Establishment of Hematopoietic cell transplantation program in developing countries : Guidelines from the francophone Society of bone marrow transplantation and cellular therapy (SFGM-TC)]. Bull Cancer 2021; 108:S10-S19. [PMID: 34247762 DOI: 10.1016/j.bulcan.2021.02.015] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/15/2021] [Revised: 02/23/2021] [Accepted: 02/24/2021] [Indexed: 12/26/2022]
Abstract
Hematopoietic cell transplantation (HCT) is the curative treatment for many malignant and non-malignant blood disorders and some solid cancers. However, transplant procedures are considered tertiary level care requiring a high degree of technicality and expertise and generating very high costs for hospital structures in developing countries as well as for patients without health insurance. During the 11th annual harmonization workshops of the francophone Society of bone marrow transplantation and cellular therapy (SFGM-TC), a designated working group reviewed the literature in order to elaborate unified guidelines, for developing the transplant activity in emerging countries. Access to infrastructure must comply with international standards and therefore requires a hospital system already in place, capable of accommodating and supporting the HCT activity. In addition, the commitment of the state and the establishment for the financing of the project seems essential.
Collapse
Affiliation(s)
- Nabil Yafour
- Établissement hospitalier et universitaire 1(er) Novembre 1954, service d'hématologie et de thérapie cellulaire, BP 4166 Ibn Rochd, université d'Oran 1, Ahmed Ben Bella, faculté de médecine, 31000 Oran, Algérie.
| | - Mohamed Amine Bekadja
- Établissement hospitalier et universitaire 1(er) Novembre 1954, service d'hématologie et de thérapie cellulaire, BP 4166 Ibn Rochd, université d'Oran 1, Ahmed Ben Bella, faculté de médecine, 31000 Oran, Algérie
| | - Patrice Chevallier
- CHU de Nantes, service d'hématologie clinique, Hôtel-Dieu, place Alexis-Ricordeau, 44035 Nantes, France
| | - Quentin Cabrera
- CHU Réunion Sud, service d'hématologie clinique, Site de Saint Pierre, La Réunion, France.
| | - Tereza Coman
- Institut Gustave-Roussy, département d'hématologie, 114, rue Edouard-Vaillant, Villejuif, France
| | - Maria Elkababri
- Hôpital d'enfants de Rabat, service d'hématologie et oncologie pédiatrique, université Mohammed V de Rabat, Maroc
| | - Faty Hamzy
- Hôpital Cheikh Zaïd universitaire international, service d'hématologie et greffe, Cite al Irfane-Hay Ryad avenue Allal al Fassi, 10000 Rabat, Maroc
| | - Asmaa Quessar
- Hôpital 20-Août de Casablanca, 6, rue Lahssen Elaarjoun, Casablanca 20250, Maroc
| | - Amal Laamiri
- Hôpital Cheikh Zaïd universitaire international, service d'hématologie et greffe, Cite al Irfane-Hay Ryad avenue Allal al Fassi, 10000 Rabat, Maroc
| | - Cécile Pochon
- Hôpital Brabois, service d'hémato-oncologie pédiatrique, rue du Morvan, 54500 Vandœuvre-les-Nancy, France
| | | | - Mhamed Harif
- Centre Hospitalier Tanger-Tétouan-Al Hoceima (Tanger), faculté de médecine et de pharmacie, Casablanca, Maroc
| |
Collapse
|
3
|
Tarillon S, Andrianne C, Balcaen S, Bole S, Genty C, Godin S, Lemarchand E, Mouchebeuf J, Mussot I, Wallart A, Alsuliman T, Desbrosses Y, El Cheikh J, Guerout-Verite MA, De Vos J, Tardieu L, Yakoub-Agha I, Porcheron S. [Graft reinjection: Guidelines from the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC)]. Bull Cancer 2018; 106:S83-S91. [PMID: 30528618 DOI: 10.1016/j.bulcan.2018.11.001] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/27/2018] [Revised: 10/31/2018] [Accepted: 11/01/2018] [Indexed: 11/28/2022]
Abstract
JACIE (Joint Accreditation Committee ISTC EBMT) regulations and standards impose a quality and safety requirement for graft reinjection by nurses. However, the standards do not provide a step-by-step graft reinjection procedure. Because of high medical team turnover, the opening of new transplant centers, and continual questions from colleagues trying to decipher the JACIE standards, the need for a specific procedure goes without saying. We collected graft reinjection procedures from each SFGM-TC center that participated in our survey, thus creating an inventory of the different steps that make up graft reinjection. In addition to reviewing the main regulatory texts and JACIE standards, we sought advice from medical and cellular therapy experts. We observed that most centers use a mix of practices and some unjustified practices. In some transplant units, it is still standard practice to defrost cell therapy products in the transplant unit. Caregivers are aware of the need for a rigorous application of the regulatory requirements and are willing to administer a procedure that provides specific steps for each stage of the process. In this workshop, we questioned each stage of the graft reinjection procedure, which helped us define clear methods of implementation. In the form of a checklist, we offer bone marrow and stem cell transplant units a step-by-step procedure.
Collapse
Affiliation(s)
- Sylvie Tarillon
- CHRU Brabois Nancy, unité de soins intensifs d'hématologie, rue du Morvan, 54511 Vandœuvre-lès-Nancy, France.
| | - Christelle Andrianne
- CHU de Liège, hématologie clinique, domaine de Saint-Tilmon B35, 4000 Liège, Belgique
| | - Sandie Balcaen
- CHRU de Lille, hôpital Huriez, service des maladies du sang, rue Michel Polonowski, 59000 Lille cedex, France
| | - Sarah Bole
- CHRU de Besançon, unité de soins intensifs hématologie, boulevard Fleming, 25000 Besançon, France
| | - Carole Genty
- CHRU Dupuytren, hématologie clinique et de thérapie cellulaire, 2, avenue Martin-Luther-King, 87042 Limoges cedex, France
| | - Sandrine Godin
- CHRU de Lille, hôpital Jeanne-de-Flandre, hématologie pédiatrique, avenue E.-Avinée, 59037 Lille cedex, France
| | - Eva Lemarchand
- CHU de Rouen, onco-hémato-pédiatrie, 1, rue de Germont, 76000 Rouen, France
| | - Jérôme Mouchebeuf
- Hôpital Pitié-Salpêtrière, unité de thérapie cellulaire, 47, boulevard de l'Hôpital, 75013 Paris, France
| | - Isabelle Mussot
- CHRU de Besançon, unité de soins intensifs hématologie, boulevard Fleming, 25000 Besançon, France
| | - Anne Wallart
- CHRU de Lille, hôpital Huriez, service des maladies du sang, rue Michel-Polonowski, 59000 Lille cedex, France
| | - Tamim Alsuliman
- CHRU de Lille, hôpital Huriez, service des maladies du sang, rue Michel Polonowski, 59000 Lille cedex, France; Centre hospitalier de Boulogne-sur-Mer, 62321 Boulogne-sur-Mer, France
| | - Yohann Desbrosses
- CHRU de Besançon, unité de soins intensifs hématologie, boulevard Fleming, 25000 Besançon, France
| | - Jean El Cheikh
- American University of Beirut Medical Center, Beyrouth, Liban
| | | | - John De Vos
- CHU de Montpellier, hôpital Saint-Éloi, unité de thérapie cellulaire, 80, avenue Augustin-Fliche, 34295 Montpellier, France
| | - Laure Tardieu
- Centre hospitalier Dupuytren, service d'hématologie, 2, avenue Martin-Luther-King, 87042 Limoges cedex, France
| | - Ibrahim Yakoub-Agha
- CHRU de Lille, hôpital Huriez, service des maladies du sang, rue Michel Polonowski, 59000 Lille cedex, France; Université de Lille2, LIRIC, Inserm U995, 59000 Lille, France
| | - Sophie Porcheron
- Unité de soins intensifs, CLCC Becquerel, 1, rue d'Amiens, 76000 Rouen, France
| |
Collapse
|
4
|
De Vos J, de Berranger E, Jubert C, Pochon C, Letellier C, Mialou V, Sirvent A, Yakoub-Agha I, Dalle JH. [Preservation/congelation of hematopoietic stem cell grafts in a pediatric context: Guidelines from the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC)]. Bull Cancer 2017; 104:S136-S141. [PMID: 29169651 DOI: 10.1016/j.bulcan.2017.04.008] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/20/2017] [Accepted: 04/30/2017] [Indexed: 11/25/2022]
Abstract
The Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC) organized the 7th allogeneic hematopoietic stem cell transplantation clinical practices harmonization workshop series in September 2016 in Lille, France. The objective of our workshop is to provide a discussion on the conservation and congelation of hematopoietic stem cells in a pediatric setting as well as our recommendations for this technique.
Collapse
Affiliation(s)
- John De Vos
- CHU de Montpellier, unité de thérapie cellulaire, 80, avenue Fliche, 34295 Montpellier cedex 5, France
| | - Eva de Berranger
- CHRU de Lille, hôpital Jean-de-Flandre, service pédiatrie et hématologie, rue Eugène-Avinée, 59037 Lille cedex, France
| | - Charlotte Jubert
- CHU Bordeaux, hôpital des enfants, unité d'hématologie oncologie pédiatrique, place Amélie-Raba-Léon, 33000 Bordeaux, France
| | - Cécile Pochon
- CHU de Nancy, service d'hématologie, unité de transplantation médullaire allogénique, 54500 Vandœuvre-lès-Nancy, France
| | | | - Valérie Mialou
- Centre hospitalier Lyon Sud, établissement français du sang (EFS) Rhône Alpes, cell therapy laboratory, 69310 Pierre-Bénite, France
| | - Anne Sirvent
- CHRU de Montpellier, département d'onco-hématologie pédiatrique, 34295 Montpellier, France
| | | | - Jean-Hugues Dalle
- Université Paris 7, hôpital Robert-Debré, service d'hémato-immunologie, 75019 Paris, France.
| |
Collapse
|